Grifols, S.A. (NASDAQ:GRFS) Shares Bought by Janus Henderson Group PLC

Janus Henderson Group PLC lifted its position in shares of Grifols, S.A. (NASDAQ:GRFS - Free Report) by 11.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 3,045,260 shares of the biotechnology company's stock after purchasing an additional 324,869 shares during the quarter. Janus Henderson Group PLC owned about 0.44% of Grifols worth $22,642,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Barclays PLC grew its stake in Grifols by 381.2% during the third quarter. Barclays PLC now owns 592,552 shares of the biotechnology company's stock worth $5,261,000 after buying an additional 469,401 shares during the period. Blue Trust Inc. lifted its holdings in shares of Grifols by 254.0% during the 4th quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company's stock valued at $52,000 after acquiring an additional 4,970 shares in the last quarter. Helikon Investments Ltd acquired a new position in shares of Grifols during the 4th quarter valued at $580,000. R Squared Ltd purchased a new stake in Grifols during the 4th quarter worth $28,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in Grifols by 10.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 25,867 shares of the biotechnology company's stock valued at $192,000 after purchasing an additional 2,403 shares in the last quarter.

Grifols Stock Up 2.4%

Shares of GRFS stock traded up $0.20 on Wednesday, hitting $8.24. The stock had a trading volume of 113,521 shares, compared to its average volume of 1,161,972. The stock's 50 day moving average is $7.30 and its 200-day moving average is $7.62. The firm has a market capitalization of $5.66 billion, a price-to-earnings ratio of 7.04 and a beta of 0.44. Grifols, S.A. has a 52-week low of $5.79 and a 52-week high of $9.96. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26.

Analyst Ratings Changes

A number of research analysts have commented on GRFS shares. StockNews.com upgraded Grifols from a "hold" rating to a "buy" rating in a research note on Thursday, May 15th. Morgan Stanley began coverage on Grifols in a research report on Wednesday, February 12th. They set an "overweight" rating on the stock.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.